F.D.A. seeks increased oversight of vaccine trials and approvals
Key stakeholders, including health experts and pharmaceutical companies, have expressed mixed reactions to the F.D.A.’s proposed changes. Some advocates argue that increased scrutiny is necessary to rebuild public trust in vaccines, especially following the rapid rollout of COVID-19 vaccines, as discussed in the ongoing dialogue about vaccine oversight. Others caution that overly stringent regulations could … Read more